Dupilumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Dupilumab and local guidelines before prescribing.
Mechanism
IL-4 and IL-13 receptor monoclonal antibody.
Uses
Atopic dermatitis, asthma, chronic rhinosinusitis with polyps, eosinophilic oesophagitis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Injection-site reactions, conjunctivitis, eosinophilia, herpes infections.
Interactions
Live vaccines contraindicated.
Contraindications and cautions
Active parasitic infection
Monitoring
Eosinophils, eye symptoms
Pregnancy and breastfeeding
Limited data
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Treat helminth infection before starting; conjunctivitis common in eczema patients.
More from the textbook: uses, cautions and other points
- Dupilumab | IL-4 receptor alpha (blocks IL-4 and IL-13) | Severe type 2 asthma (raised eosinophils or FeNO); also eczema, nasal polyps; can cause conjunctivitis and a rise in eosinophils
Respiratory: Anatomy, Physiology and Pharmacology - Omalizumab / mepolizumab / benralizumab / dupilumab / tezepelumab | Biologics for severe asthma (specialist).
Respiratory: Anatomy, Physiology and Pharmacology - Dupilumab (anti-IL-4 receptor alpha - blocks IL-4 and IL-13): Type 2 asthma with raised eosinophils and FeNO. Also treats nasal polyps and eczema.
Respiratory: Airways Disease - Leukotriene antagonists may help; specialist desensitisation; dupilumab for polyps.
Respiratory: Airways Disease - Dupilumab (biologic): NICE (TA1142) recommends it as an add-on for uncontrolled COPD with raised blood eosinophils despite triple therapy (or dual therapy if ICS is unsuitable). Uncontrolled means 1 or more severe, or 2 or more moderate, exacerbations in the past year.
Respiratory: Airways Disease - Biologics (asthma) | Omalizumab (anti-IgE), mepolizumab, reslizumab, benralizumab (IL-5 pathway), dupilumab (IL-4/13), tezepelumab (TSLP) - specialist, NICE criteria.
Respiratory: Airways Disease - Dupilumab (COPD) | Add-on for uncontrolled COPD with raised eosinophils despite triple therapy (NICE TA1142).
Respiratory: Airways Disease - Consider dupilumab if exacerbations continue on triple therapy.
Respiratory: Airways Disease
Where it is discussed in the book
- Respiratory: Anatomy, Physiology and Pharmacology (2 mentions)
- Respiratory: Airways Disease (7 mentions)
- Gastroenterology: Oesophagus and Stomach (1 mention)
- Dermatology: Skin basics, eczema and psoriasis (3 mentions)
- Dermatology: Urticaria, drug reactions, blistering, ulcers and emergencies (1 mention)
- ENT Anatomy Physiology (1 mention)
- Clinical Immunology: Immune system basics and immunological investigations (3 mentions)
- Clinical Immunology: Allergy, anaphylaxis, urticaria and angioedema (3 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (3 mentions)
- Integrated respiratory chapter (7 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)